Holen Sie sich die Stockscreener-App
276.47
1.49%
4.05
Handel nachbörslich:
276.43
-0.04
-0.01%
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
HSBC Raises AbbVie Price Target to $315 on Immunology Drug Label Expansions - NAI500
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold? - Yahoo Finance
HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English. - Yahoo Finance
AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says - marketscreener.com
Abbvie-Genmab Epkinly data signal first-line filing for DLBCL - BioWorld News
AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770 - AD HOC NEWS
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
UBS reiterates Abbvie stock rating on positive cancer trial data By Investing.com - Investing.com Canada
Should You Buy AbbVie Stock Before Oct. 30? - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - Yahoo Finance
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News - 24/7 Wall St.
Genmab jumps after positive trial of AbbVie-partnered lymphoma drug - Sharecast.com
IYH Beats IXJ on Returns While Global Fund Offers Higher Yield - The Motley Fool
BofA raises target for AbbVie stock from USD 282.00 to USD 289.00 - AD HOC NEWS
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
A lymphoma drug combination cut the risk of worsening or death by 51% in a trial. - Stock Titan
Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study - Reuters
AbbVie (ABBV) Flags $216M IPR&D Expense Impacting Q3 and Full-Ye - GuruFocus
Why AbbVie (ABBV) Outpaced the Stock Market Today - Zacks Investment Research
Why AbbVie (ABBV) Outpaced the Stock Market Today - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
An estimated $216M Q3 expense lowers AbbVie (ABBV)'s 2026 adjusted earnings outlook. - Stock Titan
Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October - The Motley Fool
Better Dividend for Retirees: AbbVie vs. Merck - Yahoo Finance
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting - Zacks Investment Research
AbbVie Announced Its 340B Rebate Pilot on October 2. Here’s What It Means for the Stock Before Vraylar’s 2027 Medicare Price Cut - Yahoo Finance
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB - The Motley Fool
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think. - Yahoo Finance
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP - The Motley Fool
How to Create a Million-Dollar Stock Portfolio - Zacks Investment Research
AbbVie joins US government pilot to test drug discount rebates - Reuters
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie Stock: Buy, Sell, or Hold in October? - Yahoo Finance
AbbVie Stock: Buy, Sell, or Hold in October? - The Motley Fool
Novo Nordisk Gives Uninspiring Outlook - The Motley Fool
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research
Defensive Dividends: 3 Companies Investors Can Rely On - Zacks Investment Research
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - Kalkine Media
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - Yahoo Finance
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - GuruFocus
2.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):